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Olive-pollen allergy is one of the leading causes of respiratory allergy in Mediterranean countries and 
some areas of North America. Currently, allergen-specific immunotherapy is the only etiophatogenic 
treatment. However, this approach is not fully optimal, safe, or effective. Thus, efforts continue in 
the search for novel immunotherapy strategies, being one of the most promising the use of peptides 
derived from major allergens. This work tries to determine the therapeutic potential and safety of 5 
dodecapeptides derived from the main allergen of olive-pollen allergy, Ole e 1. The immunomodulatory 
capacity of these peptides was studied using peripheral blood mononuclear cells (PBMCs) obtained from 
19 olive-pollen-allergic patients and 10 healthy controls. We determined the capacity of these peptides 
to inhibit the proliferative response toward olive-pollen allergenic extract and to induce the regulatory 
cytokines, IL-10 and IL-35. To test the safety and absence of allergenicity of the peptides, the basophil 
activation was analyzed by flow-cytometry, using peripheral blood. The results showed that two of 
five peptides inhibited near to 30% the proliferative response against the total olive-pollen allergenic 
extract in olive-pollen-allergic patients. Inhibition increased to nearly 35% when the 5 peptides were 
used in combination. In both cases, a statistically significant induction of IL-10 and IL-35 secretion 
was observed in the supernatants of allergic patients PBMCs cultures. None of the 5 peptides induced 
basophil activation and cross-link inflammatory cell-bound IgE. In conclusion, these results open up 
new possibilities in the treatment of olive-pollen allergy, which could solve some of the problems facing 
current therapy approaches.
Peripheral T-cell tolerance of environmental substances is tightly controlled by the immune system due to the 
functional deactivation caused by specific T-cell subtypes, generically called regulatory T-cells (Tregs), which 
have an immunosuppressive effect. The secretion of traditional regulatory cytokines, such as interleukin (IL)-10, 
and novel related molecules, such as IL-35, are some of the most important mechanisms involved in the immune 
response1. However, under certain environmental conditions, an imbalance in these regulatory mechanisms 
can induce allergic diseases, promoting allergen-specific IgE production as well as activation and recruitment of 
pro-inflammatory cells in target organs1,2.
Allergic diseases are a global health problem, affecting up to 25% of the population in industrialized socie-
ties3,4. To date, allergen-specific immunotherapy (AIT) is the only treatment that can change the course of these 
diseases. Although AIT has been used for over 100 years5, treatment with whole-allergen extracts is not without 
its drawbacks, as AIT can cause local and systemic adverse events and may produce new IgE sensitization to other 
allergens present in the extract. Furthermore, the lengthy treatment duration (3–5 years), frequent administra-
tion, and high treatment cost are among the other disadvantages of AIT6,7. For these reasons, there is a need for 
safer and more effective AIT strategies.
Immunotherapy based on modified allergens or peptides has been considered since more than 20 years, how-
ever, the last advances in molecular biology of allergens and the mechanisms implicated in their recognition and 
the modulation of their responses have increased the number of experimental and clinical trials to try to improve 
the immunotherapy guidelines, and the peptides therapy is one of the most promising treatments in course8. This 
therapy for allergic disease involves the use of soluble allergen fragments of variable lengths and peptide-based 
vaccines, which could solve several of the main problems facing conventional AIT. This approach also offers 
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additional advantages, such as high stability, ease of purification, standardization, and low production costs. In 
addition, the therapeutic dose may be used without the need of dose escalation6,9. Peptide vaccines are designed 
based on the primary structure of the allergen. There are two types of peptides, depending on the length of the 
fragments and their capacity to induce tolerance: IgE-mediated peptides, which are long peptides, having a length 
of 20 to 40 amino acids (aa); and synthetic peptide immuno-regulatory epitopes (SPIRE), consisting of T-cell 
tolerizing peptides made up of smaller peptide units (10 to 17 aa)10,11.
One of the most prevalent types of pollinosis in Mediterranean countries and some areas of North America is 
caused by the pollen of olive trees. This pollen mainly induces nasal and conjunctival symptoms and may cause 
asthma exacerbation in areas with high antigenic load, such as Andalusia, a region in Spain where olive tree is 
widely cultivated and with particularly high pollen counts during the pollen season (5,000 grains/m3, with peaks 
reaching more than 10,000 grains/m3). The incidence of pollinosis is high during pollen season, lasting from 
mid-April to the end of June12. The main allergen, Ole e 1, recognized by almost 80% of allergic subjects, is a 
145-aa glycoprotein with microheterogeneity of sequence, highly dependent on the olive cultivar analyzed13,14 
but a high degree of sequence homology and IgE cross-reactivity to the main allergens in other Oleaceae-family 
pollens, such as lilac, ash, and privet15. Ole e 1 has at least 4 B-cell epitopes16 and 2 regions, aa 91 to 102 and 
aa 119 to 130, which were defined as immunodominant T-cell epitopes, or the regions mainly recognized by 
olive-pollen-allergic patients, able to induce a T cell-proliferative response with no IgE-binding capability17. In 
addition, a pilot study of our group showed how stimulation with Ole e 1 peptides derived from the sequence of 
Ole e 1 obtained after Edman degradation18, induced a different cytokine profile in peripheral blood mononuclear 
cells (PBMCs) from olive-pollen-allergic patients compared to nonallergic subjects. Two peptides that included 
the aa11-33 Ole e 1 region were mainly recognized by nonallergic subjects and induced IL-10 levels in vitro, which 
is why they were postulated as possible immunoregulatory peptides19. More recently, we explored how these Ole 
e 1-derived peptides affect gene-expression profile and we examined their in vitro capacity to modulate the Th1/
Th2 response. In our previous article, we reported that these peptides were capable of modulating some genes 
implicated in the tolerance response, which could be of interest in the effort to develop a new immunomodulatory 
treatment20.
In this report, we expand the body of research into the use of short Ole e 1-derived peptides as a new prom-
ising method in the treatment of olive-pollen allergy. We carried out an in vitro analysis of the ability of combi-
nations of Ole e 1 immunomodulatory peptides to prevent or reverse the olive pollen response and their safety 
(absence of basophil activation). We also analyzed the implication of the classical regulatory cytokine, IL-10, as 
well as the new regulatory cytokine, IL-35, in this modulation, to establish the potential of these peptides as future 
immunotherapeutic tools for this disorder.
IL-35, the newest member of the IL-12 family, is secreted mainly by stimulated Tregs21. It is a heterodimer 
composed of IL12 p35 and EBI322, but, in contrast to the rest of IL-12 family (IL-12, IL-23, IL-27) that are 
involved in the pro-inflammatory response, IL-35 mediates immunological functions by suppressing inflamma-
tory immune response. Besides, this cytokine was analyzed in this study because EBI3 was one of the genes that 
we previously find as specifically modulated by peptides 2 and 3 and, considered as a possible therapeutic target 
for olive-pollen allergy20. Our results point that Ole e 1 peptides could induce a regulatory response mediated by 
IL-35 and IL-10, being able to reduce the olive pollen response, and reinforcing the idea of these peptides as useful 
therapeutic tools for preventing these respiratory disorders.
Material and Methods
Subjects. The study population comprised 19 untreated olive-pollen-allergic patients, including 13 asthmatic 
olive-pollen-allergic subjects and 6 nonasthmatic subjects with the same allergy. Ten nonallergic subjects were 
used as healthy controls. All patients were diagnosed and recruited from the allergy departments of two hospitals 
located in Seville and Granada, both in Andalusia, a region of southern Spain chosen for its high olive-pollen 
counts. Nonallergic control subjects were healthy and had no history of respiratory allergy. Biological samples 
from subjects were obtained outside the pollen season, from October to December, when environmental pollen 
counts are low.
Olive-pollen-allergic patients fulfilled the following criteria established in accordance with EAACI recom-
mendations: rhinitis or rhinitis with asthma from April to June, with a positive skin prick test for O. europaea 
pollen extract (ALK Abelló, Madrid, Spain) and no previous immunotherapy (EAACI, 1989). The exclusion cri-
teria were as follows: age under 16 years, less than 10 years’ residence in the study area, and corticosteroid or 
anti-histaminic treatment.
Total and specific IgE antibody measurements. Ten to 20 ml of peripheral heparin blood samples and 
10 ml of blood without anticoagulant were obtained from each study subject for cellular and serological analysis. 
Total serum IgE levels were determined using an IgE enzyme immunoassay (Phadia, Uppsala, Sweeden), O. euro-
paea pollen-specific IgE and Ole e 1-specific IgE antibody levels were quantified by UNI-CAP system (Phadia). 
Levels of specific IgE > 0.35 kUA/l were considered positive.
Olive-tree pollen extract and Ole e 1 peptide purification. Olive-tree pollen was obtained from 
Allergom AB, Sweden. The pollen (5% w/v) was extracted with 50 mM ammonium bicarbonate, pH 8.0, con-
taining 1 mM phenyl-methyl-sulfonyl-fluoride, followed by centrifugation at 12 000 × g for 20 min at 4 °C. The 
lyophilized supernatant was stored at −20 °C.
Ole e 1 dodecapeptides were synthesized (purity > 90%) according to the Ole e 1 amino-acid sequence18. The 
peptides used were as follows: peptide (P) 2 (aa11-22: FHIQGQVYCDTC), P3 (aa22-33: CRAGFITELSEF), P10 
(aa91-102: NEIPTEGWAKPS), P12 (aa109-120: TVNGTTRTVNPL), and P13 (aa119-130: PLGFFKKEALPK), 
all as previously were described17,19,20.
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PBMC isolation and culture. PBMCs were isolated from heparin-containing peripheral blood samples by 
gradient centrifugation on Lymphoprep (Comercial Rafer, Zaragoza, Spain) following the manufacturer’s instruc-
tions. PBMCs were cultured in triplicate in a P96-U-bottom plate (Costar, New York, USA) at a density of 1 × 106 
cells/ml, in RPMI 1640 (Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (FBS) inactivated 
(Lonza), 1% glutamine (Gibco, Carlsbad, California, USA),1% peni-streptomycin (Gibco), and 1 mM sodium 
pyruvate (Gibco) in the absence or presence of olive-pollen stimuli, over 6 days, 37 °C, 5% CO2 in humidified air, 
as was previously described17,19,20.
The different stimuli were as follows: olive-pollen extract (Olea europaea, 25 µg/ml) named “Olea”, peptides 2 
and 3 (P 2 + 3, 5 µg/ml), peptides 10, 12, and 13 (P 10 + 12 + 13, 5 µg/ml), and the combination of all of peptides, 
peptides 2, 3 (5 µg/ml) and peptides 10, 12, and 13 (5 µg/ml). PHA (10 µg/ml) was used as a positive control. 
Concentration and combination of stimuli were based on previous assays17. All stimuli were reconstituted in 
RPMI medium. Figure 1a presents an overview of the protocol used.
After stimulation and plate centrifugation (10 min, 720 g), supernatants were used to measure soluble cytokine 
levels and cells were then resuspended in 100 µl of fresh culture medium. To quantify the levels of proliferation, 
20 µl of Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, USA) was added to each 
well, following the manufacturer’s instructions. After 90 minutes, absorbance at 490 nm was measured with the 
microplate reader Infinite F200 (Tecan, Männedorf, Switzerland), and the average absorbance values from three 
wells per experimental condition were calculated. The stimulation index was determined as the ratio of average 
absorbance of each condition and basal condition (without stimulation). Only those assays that showed a positive 
value for the ratio of PHA/basal were considered valid. Also, it was measured the cell viability by Trypan blue 
(Gibco) method, being always higher than 80%.
Inhibition of PBMC proliferative response. In order to demonstrate the immunomodulation properties 
of the peptides, we designed two types of inhibition proliferation assay. An overview of the protocol used is given 
in Fig. 1b,c. Optimal inhibition conditions were established by time curve studies (see Supplementary Fig. S1).
Reversion of response assays: PBMCs (1 × 106 cells/ml) were cultured in the presence of olive-pollen extract 
for 6 days; after 24 hours, peptides 2 and 3 (P2 + 3, 5 µg/ml), peptides 10, 12, and 13 (P10, 12, and 13, 5 µg/ml), 
or the combination of all peptides (peptides 2, 3 (5 µg/ml) and peptides 10, 12, and 13 (5 µg/ml)), as appropriate, 
were added to the medium of these PBMCs.
Figure 1. Scheme of proliferation and/or inhibition of PBMCs assays. PBMCs from the study subjects were 
cultured with different combinations of peptides or/and olive-pollen extract (Olea) as indicate the figure, for 6 
days, in order to determine: the proliferative response (a), reversion of the response (b) or inhibition response 
(c). Three different combinations of peptides were used: peptides 2 and 3 (immunoregulatory region); peptides 
10, 12, and 13 (immunodominant region), and both groups of peptides. After 6 days of stimulation, proliferative 
response was measured. Also, supernatants (SN) were collected for a subsequent study of cytokine secretion.
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Prevention of response assays: PBMCs (1 × 106 cells/ml) were cultured in the presence of peptides 2 and 3 
(P2 + 3, 5 µg/ml), peptides 10, 12, and 13 (P10, 12, and 13, 5 µg/ml), or the combination of all peptides (peptides 
2, 3 (5 µg/ml) and peptides 10, 12, and 13 (5 µg/ml)), for six days, adding 25 µg/ml of olive-pollen extract to the 
medium after 24 hours.
In both cases, absorbance was measured and compared to stimulation with olive pollen extract only, that was 
named “Olea” condition, whose proliferation was taken to be 100%.
Measurement of soluble cytokine levels. All the supernatants collected in the cellular assays were stored 
at −80 °C until use to measure soluble cytokine levels. Levels of two soluble regulatory cytokines—IL-10 and 
IL-35—were analyzed. IL-10 was measured in supernatant of proliferation and inhibition-of-response assays of 
all patients and controls, using ELISA (ImmunoTools, Germany), although in two patients the levels of IL-10 
were under the detection threshold (9.8 pg/ml). IL-35 was measured in the supernatants of 9 control assays and 
17 olive-pollen-allergic patient assays, also by ELISA (Elabscience, Houston, Texas, USA), but one patient was 
desestimated because the levels of IL-35 were over the detection threshold (1000 pg/ml). IL-4 (ImmunoTools, 
Germany), IFN-γ (ImmunoTools, Germany) and TGF-β (R&D Systems, Minneapolis, USA) were also measured 
in a percentage of the population studied (6 healthy control subjects and 7 allergic subjects), but without any 
conclusive result related with the stimuli (data not shown).
Basophil activation test. As fresh heparinized blood is needed for this test, 3 olive-pollen-allergic patients 
and 3 healthy control subjects were recruited outside pollen season from the Fundación Jiménez Díaz hospital in 
Madrid, Spain, with the same criteria than the population of study. Informed consent was obtained from each 
subject, and ethical approval was granted by the ethical and research committee of the hospital. Total IgE and O. 
europaea- and Ole e 1-specific IgE-antibody determinations were performed in the allergy department of the 
hospital.
Basophil activation test was performed to test peptide safety using the BasoFlowEx® Kit (EXBIO 
Diagnostics, Huissen, Netherlands) according to the manufacturer’s instructions. Briefly, 100 µl of hepa-
rinized whole blood samples was incubated for 15 minutes at 37 °C with different stimuli: control (anti-IgE 
monoclonal antibody as positive control sample), 3 concentrations of olive-pollen extract (5, 25, and 125 µg/
ml), 3 concentrations of peptides 2 and 3 and/or 10, 12, and 13 (1, 5, and 25 µg/ml), or nothing (negative 
control). The concentrations tested were based in the optimal extract or peptide dose conditions, 25 µg/ml 
for olive pollen extract and 5 µg/ml for peptides respectively, as was previously described [16], checking two 
more conditions: 5 times higher and 5 times lower. Samples were then labeled with PE-anti human CD203c 
antibody to select the basophil population, and FITC-anti human CD63 antibody to identify the activated 
basophils. Samples were immediately analyzed by Facs Canto II flow cytometer (Becton-Dickinson BD, San 
Jose, California, USA).
Data acquisition was carried out on 100,000 events, and the results of basophil activation were analyzed with 
the Infinicyt™flow cytometry software (Cytognos, Salamanca, Spain). Only those assays with a positive control 
higher than 20% were considered reliable. Activation > 15% by stimuli was considered positive, according to the 
manufacturer’s instructions.
Statistical analysis. Statistical analyses were carried out using GraphPad InStat software. IgE levels and 
the results of proliferation and ELISA assays were analyzed by Mann-Whitney test. Prevention and reversion of 
response assays were analyzed by Wilconxon test, comparing their medians to the olive-pollen condition median 
(100%).
Ethical approval. Written informed consent in accordance with the Declaration of Helsinki was obtained 
from each subject. Ethical approval for the study was obtained from the ethical and research committees of the 
participating hospitals (IIS-Fundación Jiménez Díaz, Vírgen del Rocío and San Cecilio University Hospitals Ethical 
and research Committes).
Results
Study population. The demographic and clinical characteristics of the study population, grouped by clin-
ical condition, appear in Table 1. Individual´s data are enclosed as Supplementary Table S1. Mean age was sig-
nificantly higher in the nonallergic control group compared to the overall allergic group and asthmatic allergic 
subjects. There were no differences in sex between the nonallergic and overall olive-pollen-allergic group, though 
the percentage of asthmatic women among the olive-pollen-allergic subjects was higher than in the group of non-
asthmatic olive-pollen-allergic subjects. All groups contained both smokers and nonsmokers, although most were 
nonsmokers. All allergic patients had rhinitis, and 68% also had asthma. Allergic patients were graded according 
to disease severity as mild (33.3%) or moderate (66.7%) allergy.
The mean levels of total IgE were higher in the overall group of olive-pollen-allergic patients (425.4 ± 559.3 
IU/ml) compared to the control group (175.0 ± 224.80 IU/ml), though this difference was not statistically sig-
nificant. According to specific IgE levels, the control group was negative to olive-pollen extract specific IgE, 
while all allergic patients showed positive specific IgE levels (>0.35 kUA/l), with a mean of 18.22 ± 27.57 kUA/l. 
Furthermore, referring to recombinant Ole e 1 specific IgE, all allergic patients had positive levels (mean levels 
of 6.89 ± 9.89 kUA/l). There were lower Ole e 1-specific IgE levels in nonasthmatic (1.81 ± 3.54 kUA/l) than in 
asthmatic (9.23 ± 11.02 kUA/l) patients, but without reaching the statistical significance.
Peptides 2 and 3 induce the lowest proliferative response in the PBMCs of olive-pollen-allergic 
patients. After 6 days of stimulation with olive-pollen extract or peptides, PBMC proliferation was analyzed. 
Figure 2a presents the results obtained in the nonallergic control group, where stimulation with peptides and 
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olive-pollen extract did not produced any significant difference. In Fig. 2b, the results from all olive-pollen-allergic 
patients are represented. In this case, PBMCs stimulated with peptides 10, 12, and 13 had the highest proliferation 
index, producing statistically significant differences compared with P2, 3 (p = 0.0056) and P2, 3, 10, 12, and 13 
(p = 0.0005). Olea stimulation also had higher proliferation index with significant differences compared to stim-
ulation with peptides 2, 3, 10, 12, and 13 (p = 0.0142).
Figures  2c,d show the results of asthmatic olive-pollen-allergic subjects and nonasthmatic 
olive-pollen-allergic subjects analyzed separately. The overall behavior was the same in both groups, though in 
the nonasthmatic olive-pollen-allergic subjects there were no significant differences. In contrast, in the asthmatic 
olive-pollen-allergic group, there were significant differences between response to Olea and to peptides 2 and 3 
(p = 0.0191) and also between Olea response and response to peptides 2, 3, 10, 12, and 13 (p = 0.0140). There were 
statistically significant differences between stimulation with peptides 10, 12, 13 and stimulation with peptides 2 
and 3 (p = 0.0006) and the combination of all peptides (p = 0.0002).
Prestimulation with peptides 2 and 3 before olive-pollen-extract stimulation reduces PBMC 
proliferation in olive-pollen-allergic patients. Once we observed the low proliferative response induced 
by peptides 2 and 3 to PBMCs of allergic subjects, we then studied the capacity of these peptides to avoid or 
reverse PBMC proliferation in response to olive-pollen-extract stimulation. To do this, PBMCs were exposed to 
peptides 2 and 3, peptides 10, 12, and 13, or both groups of peptides either 24 hours before (inhibition or preven-
tion of allergic response) or after (reversion of allergic response) olive-pollen-extract stimulation (Fig. 1b,c). The 
proliferation obtained in these conditions was compared with PBMCs stimulated only with olive-pollen extract. 
Figure 3 contains the results of these experiments.
Figure 3a depicts the results obtained in the nonallergic control group, where no differences were found 
between peptides and olive-pollen extract. However, olive-pollen-allergic patients showed a different pattern 
(Fig. 3b). Although stimulation with peptides after exposure to the whole extract caused no significant effect in 
proliferation—that is, producing an effect similar to the one obtained with olive-pollen extract only—differences 
were observed when peptides were administered before exposure to the extract; specifically, peptides 2 and 3 and 
peptides 2, 3, 10, 12, and 13 prevented the olive-pollen-derived proliferation of PBMCs. In both cases there was a 
significant decrease in proliferation after olive-pollen-extract stimulation; specifically, peptides 2 and 3 induced 
up to 22.8% inhibition (p = 0.0029), and the combination of all the peptides together—i.e. peptides 2, 3, 10, 12, 
and 13—caused up to 32.7% inhibition (p = 0.0003) when the peptides were administered first. These data could 
indicate that the peptides are more capable of preventing the olive-pollen-allergen response than inhibiting a 
previously established response.
As stated above, separate study of the asthmatic and nonasthmatic patients showed differences in peptide 
response in both groups (Fig. 3c,d). Peptides administered after olive-pollen stimulation could not revert the pro-
liferative response in either group. However, the different combinations of peptides (peptides 2 and 3 or peptides 
2, 3, 10, 12, and 13), when applied before the extract, reduced the proliferative response in both groups, though 
statistically significant differences were only found in asthmatic patients. Peptides 2 and 3 and peptides 2, 3, 10, 
n Age (years) Sex (%) Smoking Clinical diagnosis Positive skin prick test




Nonallergic control 10 45.8 ± 14.7
50% female 12.5% smoking
Non-allergic 100% Negative 175.0 ± 224.8
Olive pollen 
IgE: 0.1 ± 0.1
50% male 87.5% non-smoking Ole e 1 IgE: NA
Total Olive pollen-
allergic subjects 19 32.2 ± 12.3*
64.7% female 16.7% smoking 32% Rhinitis and no asthma
33.3% mild 
allergy
100% Olea europaea 
47.4% Phleum pratense, 
26.3% Salsola kali, 21.1% 
Cupressus sempervirens, 
21.1% Platanus acerifolia, 
15.8% Pets (cat/dog), 
15.8% Alternaria alternata, 
10,53% Hymenoptera, 
5.26% Food allergy: egg, 




IgE: 18.2 ± 27.6




Ole e 1 IgE: 
6.9 ± 9.9
•  Nonasthmatic 
Olive- pollen-
allergic subjects
6 39.2 ± 13.0
33.3% female 50% smoking
100% Rhinitis
83.3% mild 
allergy 100% Olea europaea 50% 




IgE: 18.4 ± 30.6




Ole e 1 IgE: 
1.8 ± 3.6
•  Asthmatic Olive- 
pollen-allergic 
subjects
13 28.7 ± 10.8*





100% Olea europaea 
46.2% Phleum pratense, 
38.5% Salsola kali, 30.8% 
Cupressus sempervirens, 
30.8% Platanus acerifolia, 
23.1% Pets (cat/dog), 23.1% 
Alternaria alternata, 7.7% 




IgE: 18.1 ± 22.4




Ole e 1 IgE: 
9.2 ± 11.0
Table 1. Demographic and clinical characteristics of the study population. NA: not applicable. *Statistically 
significant differences compared to nonallergic subjects (p < 0.05).
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12, and 13 induced a statistically significant decrease in the response to Olea, with 28.27% inhibition (p = 0.0011) 
and 34.79% inhibition (p = 0.0003), respectively. In nonasthmatic patients, the reduction induced by the five 
peptides did not reached the statistical significance.
Stimulation with Ole e 1-derived peptides (peptides 2 and 3) induces the secretion of IL-10 and 
IL-35. IL-10 secretion was measured in the nonallergic control group and overall olive-pollen-allergic patients. 
In both groups, there were several samples that showed undetectable levels of IL10, especially in the control 
group. The mean IL-10 levels were slightly higher in basal samples from allergic patients (36.265 ± 31.7 pg/ml) 
compared to controls (12.776 ± 12.51 pg/ml), but without statistically significant differences.
According stimuli, the behavior was similar in both groups, as peptides 2 and 3 alone or in combination with 
peptides 10, 12, and 13 showed the highest levels of IL-10. However, healthy controls did not show significant 
differences between any conditions.
The most remarkable results were seen in the olive-pollen-allergic patients. In this group, following stimula-
tion with peptides 2 and 3, IL-10 secretion increased significantly (79.64 ± 66.13 pg/ml) compared to stimulation 
in response to olive-pollen exposure (21.94 ± 21.35 pg/ml), p = 0.0283. The combination of peptides 2 and 3 with 
peptides 10, 12, and 13 (64.62 ± 63.36 pg/ml) also produced an increase in IL-10 induction, but without reach-
ing statistical significance (Fig. 4a). The reversion-of-response assays showed no differences in IL-10 secretion 
(Fig. 4b). However, pre-stimulation (Fig. 4c) with peptides 2 and 3 (76.97 ± 64.04 pg/ml) alone and in combi-
nation (74.41 ± 65.53 pg/ml) 24 hours before olive-pollen stimulation, induced significantly higher secretion of 
IL-10, compared to Olea (21.94 ± 21.35 pg/ml) (p = 0.014 and 0.036, respectively).
For control subjects none condition showed statistical significant differences. Stimulation with peptides 2 and 
3 (63.54 ± 62.69 pg/ml) and with the five peptides (55.5 ± 73.4 pg/ml) increased the IL-10 secretion compared 
with olive-pollen stimulation (7.03 ± 0.001 pg/ml) but without statistical significant differences. The reversion 
assays showed similar data than stimulation with Olea alone (7.03 ± 0.001 pg/ml) after addition of peptides 2 and 
3 (8.23 ± 8.39 pg/ml) and after stimulation with all the peptides (7.04 ± 6.65 pg/ml). Finally, the reversion assays 
results in control subjects ranged from 30.5 ± 47.7 pg/ml with peptides 2 and 3 pre-stimulation to 43.21 ± 58.3 pg/
ml after pre-stimulation with all the peptides, but without any statistical significant result.
As IL-10 and IL-35 are closely related, and given that there is a relationship between IL-35 and Treg cells, we 
also studied the effect of the selected peptides on the secretion of this interleukin. All the samples from control 
Figure 2. Proliferation of PBMCs from four experimental groups. (a) Nonallergic control (n = 9); (b) 
total olive-pollen-allergic subjects (n = 19); (c) asthmatic olive-pollen-allergic subjects (n = 13); and (d) 
nonasthmatic olive-pollen-allergic subjects (n = 6). The mean of stimulation index is represented for each 
experimental condition. Error bars represent the standard desviation of data. This stimulation index is 
calculated as the ratio of average absorbance of each condition and basal condition. *Statistically significant 
differences (p < 0.05). **Statistically significant comparison (p < 0.01). ***Statistically significant comparison 
(p < 0.001).
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subjects and olive-pollen allergic patients showed detectable levels of IL35. The mean IL-35 levels were lower in 
basal samples from allergic patients (119.47 ± 259 pg/ml) compared to controls (287.55 ± 483 pg/ml), but with-
out statistically significant differences. According to the stimuli, the behavior was similar in both groups, but 
with much higher levels in allergic patients than in controls, being these differences statistically significant in 
olive-pollen allergic patients stimulated with Olea samples (333.62 ± 483 pg/ml) compared to control subjects 
(49.28 ± 50.93 pg/ml), and in reversion with peptides 2, 3 (537.9 ± 368 pg/ml in olive-pollen allergic patients vs. 
217.8 ± 357 pg/ml, in control group) and with peptides 2, 3, 10, 12, 13 (618.3 ± 440 pg/ml in olive-pollen allergic 
patients vs. 262.72 ± 380 pg/ml, in control group).
As in the IL-10 analysis, the results shown correspond to the IL-35 secreted in proliferation (Fig. 5a), reversion 
(Fig. 5b) and prevention-of-response assays (Fig. 5c) in the olive-pollen-allergic patients. Again, stimulation with 
peptides 2 and 3 (2717.57 ± 2807.12 pg/ml) and peptides 2, 3, 10, 12, and 13 (2555.03 ± 2617.68 pg/ml) showed a 
significant increase in IL-35 secretion, compared to basal (119.79 ± 259.32 pg/ml), Olea (331.97 ± 413.88 pg/ml) 
and peptides 10, 12, and 13 (301.02 ± 526.64 pg/ml) being all these difference extremely significance (p < 0.0001). 
In control group stimulation with peptides 2 and 3 (1369.03 ± 1918.19 pg/ml) and peptides 2, 3, 10, 12, and 
13 (1229.11 ± 1541.31 pg/ml) showed statistical significant increase (p < 0.05) in IL-35 secretion, compared to 
basal (287.55 ± 483 pg/ml), Olea (49.28 ± 50.93 pg/ml) and peptides 10, 12, and 13 (126.74 ± 279.74 pg/ml). 
Additionally, the addition of peptides 24 hours latter than the olive pollen extract was unable to induce a statisti-
cally significant increase in the IL-35 secretion. However, the olive-pollen response prevention assays induced an 
increase in IL-35 levels (Fig. 5c). Pre-stimulation with peptides 2 and 3 (2776.84 ± 2456.34 pg/ml) increased the 
secretion of this interleukin by up to 8 times compared to olive pollen (p < 0.0001). In the case of the combination 
of peptides 2 and 3 with 10, 12, and 13 (3241.41 ± 3203.66 pg/ml), this increase was almost 10-fold (p < 0.0001). 
In control group, pre-stimulation with peptides 2 and 3 (1546.18 ± 1948.11 pg/ml) and the combination of pep-
tides 2 and 3 with 10, 12, and 13 (1337.62 ± 1863.37 pg/ml) also an statistical significant increase (p < 0.05) of the 
IL-35 levels was showed compared to olive pollen stimuli.
Figure 3. Inhibition results of PBMCs response to olive pollen extract with immunomodulatory peptides. 
100% proliferation was assigned to olive pollen extract (Olea) (dotted line). Results are shown in a box and 
whisker plot, with the mean, standard deviation, maximum and minimum values for the different groups: (a) 
nonallergic control (n = 9), (b) total olive-pollen-allergic subjects (asthmatic and nonasthmatic) (n = 19), (c) 
asthmatic olive-pollen-allergic subjects (n = 13); and (d) nonasthmatic olive-pollen-allergic subjects (n = 6).  
**Statistically significant comparison between each combination and Olea condition (p < 0.01). ***Statistically 
significant differences (p < 0.001).
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Figure 4. IL-10 regulatory cytokine levels in supernants of PBMCs from olive-pollen-allergic patients. 
*Statistically significant comparison p < 0.05.
Figure 5. IL-35 regulatory cytokine levels in supernants of PBMCs from olive-pollen-allergic patients. 
*Statistically significant comparison p < 0.05. ***Statistically significant comparison, p < 0.001.
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Peptides are not capable of inducing basophil activation in vitro. Basophil activation was ana-
lyzed to test the safety of the peptides in vitro. We collected blood samples from 3 nonallergic subjects and 3 
olive-pollen-allergic patients. Then, we tested 3 different concentrations of olive-pollen extract, that is, peptides 
2 and 3 and/or peptides 10, 12, and 13 (see Fig. 6 for results). In all cases, positive controls showed higher than 
50% activation. In the nonallergic control samples, neither stimulus produced basophil activation higher than 
15% (Fig. 6a). Furthermore, olive-pollen extract produced more than 50% basophil degranulation in all the 
olive-pollen-allergic samples, while the different combinations of peptides did not produce basophil activation 
(Fig. 6b).
Discussion
This report tries to demonstrate the immunoregulatory ability of peptides derived from the major allergen of olive 
pollen, in order to define new therapeutic tools for improving therapy for olive-pollen allergy. The sequence of the 
peptides used was derived from the “canonical” sequence of Ole e 1 obtained after Edman degradation18. These 
peptides were previously defined as immunodominant (peptides 10, 12, and 13) and as possible immunoregula-
tory T cell-epitopes referring to peptides 2 and 3 (aa11-33) and were characterized as stimuli that directly influ-
ence gene-expression profile, in particular modulating immunoregulatory genes17,19,20. Ole e 1 has been described 
as a polymorphic glycoprotein13,14 where a total of 21 positions out of 145 amino acids of Ole e 1 are replaced, 
approximately 15% of the whole sequence, depending of the olive cultivar studied14. Four of these amino acid 
substitutions (at positions 91, 95, 99, and 110) were related with our immunodominant peptides (included in 
peptides 10 and 12). For that, one of the possible limitations of this report could be due to the design of the pep-
tides. However, those aa changes mainly could be related with the tertiary structure, and to be important for B 
cell epitopes but in the case of T cell epitopes (short peptides) this aspect could be relevant mainly if the amino 
acidic changes were related with the anchor peptides for HLA class II binding. This aspect was previously checked 
by a T cell epitopes free program (www.imtech.res.in/raghava/propred/) and the aa changes described were not 
essential for HLA class II restriction. However, the relevance of the Ole e 1 isoforms is a very relevant aspect of 
the complexity in the olive pollen response, mainly related with the high number of olive species cultivated. This 
high diversity has been associated with Ole e 1 polymorphic sequences and this fact could have important clinical 
repercussion, at diagnostic as well as treatment levels, as has been previously discussed23. This matter should be 
studied in more detail and in other allergens24 for a better management of this complex respiratory disease.
The use of short-length peptides derived from T-cell epitopes is being studied extensively as a new approach 
in the field of immunotherapy. This kind of peptides was recently named SPIRE because of their capacity to 
induce tolerance. The main mechanisms implicated in this approach are based on the lack of conformational 
epitopes. They are designed to induce immunological tolerance by binding to MHC class-II molecules on 
antigen-presenting cells. These peptides induce Treg cells, possibly triggering the production of IL-10, TGF-β and 
inducing Foxp3 expression and increased Th1 response6,8,25.
Figure 6. Basophil activation test. (a) Nonallergic control subjects (n = 3). (b) Olive-pollen-allergic patients 
(n = 3). a1 and b1 are representative examples of histograms obtained with the different stimuli. a2 and b2 show 
the mean levels of the percentage of basophils activated in response to three different concentrations of each 
stimulus used. Activation threshold (>15%).
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One important consideration for therapy safety is that SPIRE should not bind to IgE-FcεRI on effector cells, 
so as to prevent them from cross-linking to IgE. This provides an advantage by potentially reducing the risk of 
IgE-mediated allergic reactions such as rhinitis, asthma, and pruritus11. For this reason, all candidate peptides 
must be tested both alone and in combination to ensure their inability to bind and cross-link inflammatory 
cell-bound IgE. A convenient and reliable assay to assess the clinical and functional relevance of IgE reactivity 
is the basophil activation test26. Using this assay, we demonstrated that the Ole e 1-derived peptides used in this 
study did not bind to IgE (Fig. 6).
The study was carried out in a total of 29 subjects. These individuals were recruited and characterized accord-
ing to their clinical symptoms, the results of skin prick testing for conventional allergens and humoral responses. 
These tests revealed that the highest levels of total and specific IgE were found in asthmatic patients (Table 1). 
PBMCs were challenged in vitro with different synthetic Ole e 1 dodecapeptide combinations as well as the whole 
allergenic olive-pollen extract. Proliferation assays are used to identify T-cell epitopes and to test for specific 
response to allergens, and also to develop new approaches in immunotherapy such as SPIRE27–30.
Proliferation assays showed that peptides 2 and 3 induced the lowest proliferative response in the 
olive-pollen-allergic PBMCs compared to the whole olive-pollen extract and immunodominant peptides 10, 
12, and 13 (Fig. 2). A further step involved to design a mechanism of proliferation inhibition to evaluate 
the capacity of these peptides to revert or prevent the response to the olive-pollen extract. Figure 3b shows 
how neither peptide with this design could reverse a previously established response by olive-pollen extract. 
However, peptides 2 and 3 partially prevented the total cellular response to olive-pollen extract, reducing this 
response to 22.8% when assayed alone and 32.7% when used in combination with peptides 10, 12, and 13, as 
shown by the significant decrease observed in the stimulation index of PBMCs from the untreated allergic 
subjects. Our analysis of PBMC response in allergic patients by clinical phenotype (asthmatic vs nonasthmatic) 
showed that the inhibition of peptides 2 and 3 was greater in the asthmatic patients than in the nonasthmatic 
subjects (Fig. 3c,d). All these data are in agreement with our previous results demonstrating how peptides 2 
and 3 modified the gene expression profile of untreated olive-pollen-allergic patients, mainly in those genes 
that are essential to maintaining the peripheral T-cell tolerance and which play a key role in the inflammatory 
response19.
Closely related with the regulatory response, some cytokines have a particular function controlling the 
immune system response. This study analyzed the implication of classical and novel regulatory cytokines, such as 
IL-10 and IL-35, in this modulation. IL-10 is secreted by Treg cells, which inhibits the expansion of Th2 response 
and blocks the production of IgE and mucus and the migration of effector cells to the tissues affected by allergy30. 
Peptides 2 and 3—alone and in combination with immunodominant peptides—induced IL-10, increasing the 
microenvironment that benefits immunotolerance in untreated allergic subjects (Fig. 4a). Additionally, as hap-
pened with the proliferation assays, these peptides were unable to induce the regulatory cytokines when were 
added after olive pollen extract (Fig. 4b). However, the stimulation with these peptides before exposure to the 
olive-pollen extract maintains the high levels of this cytokine (Fig. 4c). These results are in accordance with 
the high levels of IL-35 found after stimulation with peptides 2 and 3 (Fig. 5a,c), except in the reversion assays 
(Fig. 5b). These data remark that Ole e 1 peptides could induce a regulatory response, mediated by IL-35 and 
IL-10, able to reduce the response against to olive pollen, indicating that these peptides could be useful as preven-
tive therapeutic tools for these responses.
IL-35 is secreted mainly by stimulated Tregs21. It is a heterodimer composed of IL-12p35 and EBI3 subunits22, 
this last, one of the genes that we found as specifically modulated by olive-pollen peptides 2 and 3 and considered 
as a possible therapeutic target for olive-pollen allergy20. The functional implications of this cytokine are now 
being extensively studied to describe its immunosuppressive activity in different inflammatory and autoinmune 
diseases, mainly in animal model31–33. IL-35 promotes the development of regulatory T cells (Tregs) and regula-
tory B cells (Bregs) and very recently, has been described the correlation between IL-10 and IL-35 by the induc-
tion of phosphorylation of STAT1 and STAT3 in B cells, promoted by IL-3534. However, few studies of IL-35 in 
relation with allergic diseases have been performed. Recent findings suggested that expression of IL-35 is abnor-
mal in asthma, playing an important role in the pathogenesis of this disease35. It has also been described how 
people with asthma and chronic obstructive pulmonary disease (COPD) have low levels of this cytokine, though 
serum levels of the cytokine increased after immunotherapy, marking an effect associated with an improvement 
of clinical symptoms36. Finally, according with our results, very recently37 IL-35 and inducible Tregulatory 35 
cells have been described as induced by sublingual allergy immunotherapy, pointing that IL-35 therapy could be 
useful for treatment of respiratory allergic diseases38. For that, despite the limited number of patients included, 
the results of this study are very promising.
conclusion
We have demonstrated that the combination of five short dodecapeptides Ole e 1 derived-peptides is able to 
prevent the olive-pollen proliferative response associated to IL-10 and IL-35 regulatory cytokines production 
in allergic patients. Moreover, these combinations of peptides are not capable of inducing basophils activation, 
a pre-requisite for the development of a new peptide vaccine. Further basic and clinical studies are needed to 
broaden knowledge of these capacities and to confirm their possible use in routine clinical practice. Now, how-
ever, peptides hold clear potential as new tools for olive-pollen-allergy specific immunotherapy.
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